24 June 2022 - EMA’s CHMP recommended nine medicines for approval at its June 2022 meeting.
The CHMP recommended granting a marketing authorisation for COVID-19 Vaccine (inactivated, adjuvanted) Valneva for use in people from 18 to 50 years of age as primary vaccination.